vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and OP Bancorp (OPBK). Click either name above to swap in a different company.
OP Bancorp is the larger business by last-quarter revenue ($24.3M vs $18.7M, roughly 1.3× CytomX Therapeutics, Inc.). On growth, OP Bancorp posted the faster year-over-year revenue change (13.7% vs -25.7%). OP Bancorp produced more free cash flow last quarter ($23.4M vs $-15.8M). Over the past eight quarters, OP Bancorp's revenue compounded faster (11.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
OP Bancorp is the bank holding company for Open Bank, a community-oriented commercial bank headquartered in California, United States. It provides a full range of banking solutions including deposit accounts, commercial real estate loans, small business financing, and consumer lending products, primarily catering to small and medium-sized enterprises, local immigrant communities, and retail clients across Southern California.
CTMX vs OPBK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $24.3M |
| Net Profit | $-154.0K | — |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 39.2% |
| Net Margin | -0.8% | — |
| Revenue YoY | -25.7% | 13.7% |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $24.3M | ||
| Q3 25 | — | $24.5M | ||
| Q2 25 | $18.7M | $23.7M | ||
| Q1 25 | $50.9M | $22.2M | ||
| Q4 24 | $38.1M | $21.3M | ||
| Q3 24 | $33.4M | $20.7M | ||
| Q2 24 | $25.1M | $20.4M | ||
| Q1 24 | $41.5M | $19.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | $6.7M | ||
| Q2 25 | $-154.0K | $6.3M | ||
| Q1 25 | $23.5M | $5.6M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $5.4M | ||
| Q2 24 | $-6.5M | $5.4M | ||
| Q1 24 | $13.8M | $5.2M |
| Q4 25 | — | 39.2% | ||
| Q3 25 | — | 39.5% | ||
| Q2 25 | -6.9% | 35.7% | ||
| Q1 25 | 44.4% | 34.6% | ||
| Q4 24 | 46.4% | 31.2% | ||
| Q3 24 | 12.3% | 36.5% | ||
| Q2 24 | -33.7% | 37.2% | ||
| Q1 24 | 28.1% | 37.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 27.4% | ||
| Q2 25 | -0.8% | 26.7% | ||
| Q1 25 | 46.2% | 25.0% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | 26.2% | ||
| Q2 24 | -26.0% | 26.7% | ||
| Q1 24 | 33.3% | 26.7% |
| Q4 25 | — | $0.48 | ||
| Q3 25 | — | $0.45 | ||
| Q2 25 | — | $0.42 | ||
| Q1 25 | — | $0.37 | ||
| Q4 24 | — | $0.33 | ||
| Q3 24 | — | $0.36 | ||
| Q2 24 | — | $0.36 | ||
| Q1 24 | — | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $167.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $227.9M |
| Total Assets | $175.1M | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.3M | ||
| Q3 25 | — | $166.7M | ||
| Q2 25 | $49.0M | $205.4M | ||
| Q1 25 | $47.6M | $198.9M | ||
| Q4 24 | $38.1M | $134.9M | ||
| Q3 24 | $40.6M | $166.8M | ||
| Q2 24 | $43.2M | $127.7M | ||
| Q1 24 | $36.2M | $139.2M |
| Q4 25 | — | $227.9M | ||
| Q3 25 | — | $221.5M | ||
| Q2 25 | $119.9M | $213.7M | ||
| Q1 25 | $25.0M | $210.1M | ||
| Q4 24 | $-456.0K | $205.0M | ||
| Q3 24 | $-23.5M | $203.6M | ||
| Q2 24 | $-31.2M | $195.9M | ||
| Q1 24 | $-31.7M | $194.7M |
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | $175.1M | $2.6B | ||
| Q1 25 | $98.5M | $2.5B | ||
| Q4 24 | $120.5M | $2.4B | ||
| Q3 24 | $139.0M | $2.4B | ||
| Q2 24 | $159.2M | $2.3B | ||
| Q1 24 | $184.7M | $2.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $26.2M |
| Free Cash FlowOCF − Capex | $-15.8M | $23.4M |
| FCF MarginFCF / Revenue | -84.6% | 96.2% |
| Capex IntensityCapex / Revenue | 0.1% | 11.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.2M | ||
| Q3 25 | — | $23.9M | ||
| Q2 25 | $-15.8M | $-7.0M | ||
| Q1 25 | $-21.0M | $5.6M | ||
| Q4 24 | $-19.9M | $31.2M | ||
| Q3 24 | $-20.7M | $13.3M | ||
| Q2 24 | $-19.5M | $15.8M | ||
| Q1 24 | $-26.0M | $-3.2M |
| Q4 25 | — | $23.4M | ||
| Q3 25 | — | $23.4M | ||
| Q2 25 | $-15.8M | $-7.7M | ||
| Q1 25 | $-21.2M | $4.2M | ||
| Q4 24 | $-20.0M | $29.7M | ||
| Q3 24 | $-20.7M | $12.8M | ||
| Q2 24 | $-19.6M | $15.7M | ||
| Q1 24 | $-26.2M | $-3.2M |
| Q4 25 | — | 96.2% | ||
| Q3 25 | — | 95.6% | ||
| Q2 25 | -84.6% | -32.5% | ||
| Q1 25 | -41.6% | 19.0% | ||
| Q4 24 | -52.5% | 139.0% | ||
| Q3 24 | -62.1% | 61.5% | ||
| Q2 24 | -78.2% | 77.0% | ||
| Q1 24 | -63.1% | -16.6% |
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | 0.1% | 3.0% | ||
| Q1 25 | 0.2% | 6.4% | ||
| Q4 24 | 0.2% | 7.3% | ||
| Q3 24 | 0.1% | 2.8% | ||
| Q2 24 | 0.4% | 0.4% | ||
| Q1 24 | 0.3% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.57× | ||
| Q2 25 | — | -1.10× | ||
| Q1 25 | -0.89× | 1.02× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 2.45× | ||
| Q2 24 | — | 2.90× | ||
| Q1 24 | -1.89× | -0.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
OPBK
Segment breakdown not available.
